Mental Health in Brazil: The Rising Trend of Psychotropic Use

Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Never start or discontinue psychiatric treatments without guidance from a physician or psychiatrist.

Psychotropic use in Brazil has reached levels that challenge public health, with consistent growth exacerbated in recent years. Science indicates that the medicalization of social suffering has become a recurring strategy for coping with daily stresses, often ignoring precise diagnoses in favor of a rapid, chemical response.

The Escalation: A Surge in Consumption

Since the pre-pandemic period, there has been a steady increase in the consumption of controlled substances. Data compiled by Revista Contemporânea demonstrates how the health crisis accelerated this trend. Methodological heterogeneity in studies—which report prevalence rates ranging from 7.3% to 38.7%—reflects the difficulty of consolidating unified national data, as findings vary significantly depending on geographical cuts and the profile of primary care analyzed.

The Causes: Environment and Prescriptions

Work-related stress and precarious employment are direct drivers of this demand, as pointed out by the Revista Brasileira de Saúde Ocupacional. There is also the influence of pharmaceutical industry lobbying, which shapes the market through intensive medical marketing. Additionally, recent tele-health regulations in Brazil have eased access to consultations; while this democratizes care, it has also simplified the prescription of controlled substances, often without the necessary longitudinal follow-up.

Shifting Focus: From Disorders to Behavior

The focus has shifted from severe psychiatric disorders to the use of anxiolytics and stimulants for daily challenges. According to the Brazilian Journal of Health Review, there has been a significant jump in the consumption of methylphenidate and lisdexamfetamine, frequently used off-label. The Federal Council of Medicine (CFM) has warned about the need for stricter criteria to curb excessive prescriptions motivated by the pursuit of academic and professional performance.

Global Impact: Polypharmacy and Pharmacokinetics

Brazil reflects a global trend but faces unique challenges in management under its public health system, the SUS. The PESSOAS Project from the UFMG Repository reveals that psychotropic polypharmacy affects more than 80% of patients in certain samples. A relevant technical finding requiring caution is the influence of nicotine on pharmacokinetics: studies indicate it can reduce the plasma concentration of certain psychotropic drugs, altering their efficacy. This should not be viewed as a therapeutic strategy, but as a critical factor in drug interaction.

Future Trends: Monitoring and Surveillance

Pressure for more rigorous pharmacovigilance policies is set to grow. Monitoring via the SNGPC (National System for the Management of Controlled Products) is the primary tool, yet the country still lacks real-time data on long-term outcomes. The central concern remains the impact of abrupt discontinuation, which, without supervision, can worsen clinical conditions and overwhelm the healthcare system.

Opportunities: Alternatives to Drugs

There is a vast field for non-pharmacological interventions. As noted in the integrative review by SciELO - Cadernos de Saúde Coletiva, underdiagnosis in primary care often masks the need for occupational therapy and long-term psychological support, which could reduce chemical dependency and unnecessary side effects.

Risks: Dependency and Normalization

The risks are severe: increased psychological dependency and reduced workforce productivity due to side effects. The Revista Médica de Minas Gerais emphasizes that the medicalization of social distress trivializes treatment, often concealing underlying pathologies beneath a layer of chemical sedation.

Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always seek a specialist for guidance regarding psychiatric treatments.